Le Lézard
Classified in: Health
Subjects: SVY, NTA, CFG, DEI

Government of Canada invests nearly $1 million to support activities to address diabetes in Canada


Activities supported through this investment reflect priority areas identified in the Framework for Diabetes in Canada

TORONTO, June 26, 2023 /CNW/ - Diabetes is one of the most common chronic diseases, affecting approximately 3.6 million Canadians, with more than 200,000 new cases diagnosed every year. Diabetes has significant impacts on the lives of the people that it directly affects, as well as their families and broader communities.

Today, during a panel on diabetes at the World Non-Communicable Diseases Congress, Sonia Sidhu, Member of Parliament for Brampton South, on behalf of the Honourable Jean-Yves Duclos, Minister of Health, announced $998,450 in funding over three years to Diabetes Canada. This funding will allow Diabetes Canada to work with key partners to develop an inventory of successful diabetes programs, interventions, and projects to support the subsequent dissemination, adoption, and customization of these initiatives across the country.

The funding announced today is aligned with the Framework for Diabetes in Canada, which provides a common policy direction to focus efforts to address diabetes and to ensure better health outcomes for people in Canada. Diabetes Canada will advance the Framework for Diabetes in Canada by convening individuals living with diabetes, key leaders in public health, diabetes care and education, as well as cultural leaders and organizations, to share innovative and best practices to identify, prevent, and manage diabetes.

To effectively address diabetes, we need a sustained, multisectoral response involving many actors, including the public, private, health and non-governmental sectors. All sectors and levels are invited to use the Framework to guide action to address diabetes and advance opportunities in ways that meet their respective mandates and objectives, and that are adapted to their respective community contexts.

Quotes

"The affects of diabetes continue to rise in Canada and impact the lives of millions of Canadians. Together with Diabetes Canada, we will strengthen our efforts to better recognize, collaborate with, and support those living with diabetes in Canada. The project will help improve our understanding of successful programs as we work towards improving the health, well-being, and quality of life of Canadians affected by diabetes."

The Honourable Jean-Yves Duclos
Minister of Health

"We are honoured the Public Health Agency of Canada has asked us to lead this three-year process that will focus on emerging practices as part of the implementation of the Diabetes Framework. We look forward to working with leaders, experts and people affected by diabetes, to share the latest innovation and best practices in developing the programs, resources and supports that will help to improve the quality of life for people living with diabetes."

Laura Syron
President and CEO, Diabetes Canada

Quick Facts
Related products

SOURCE Public Health Agency of Canada


These press releases may also interest you

at 04:45
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....



News published on and distributed by: